Evolving into a clinical-stage organization

Creating new safe and efficacious immunotherapies for patients

Cue Biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body to transform the treatment of cancer, infectious disease and autoimmune disease. This approach leverages a natural immune response with innovative protein engineering to achieve a more controlled immune response providing greater patient benefit while reducing toxicity — areas that have traditionally challenged broadly-acting immunotherapies on the market. In a push to move new safe and efficacious immunotherapies to patients, Cue Biopharma has scaled and grown into a clinical-stage company by expanding its development work in-house.